155648-60-5 | (1-Hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-diyl)diphosphonic acid hydrate

Packsize	Purity	Availability	Price	Discounted Price
25mg	98%	in stock	$200.00	$140.00

Description

• Catalog Number: AA77683
• Chemical Name: (1-Hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-diyl)diphosphonic acid hydrate
• CAS Number: 155648-60-5
• Molecular Formula: C9H14N2O8P2
• Molecular Weight: 340.1636
• MDL Number: MFCD00890772
• SMILES: OP(=O)(C(P(=O)(O)O)(Cc1cnc2n1cccc2)O)O.O

Computed Properties

• Complexity: 439
• Covalently-Bonded Unit Count: 2
• Heavy Atom Count: 21
• Hydrogen Bond Acceptor Count: 9
• Hydrogen Bond Donor Count: 6
• Rotatable Bond Count: 4

Literature

• Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120601

• [New approved drugs for osteoporosis in Japan].

  Clinical calcium 20120601

• Reduction of metastasis, cell invasion, and adhesion in mouse osteosarcoma by YM529/ONO-5920-induced blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway.

  Toxicology and applied pharmacology 20120315

• Gastric ulcerogenic and healing impairment effects of risedronate, a nitrogen-containing bisphosphonate in rats. Comparison with alendronate and minodronate.

  Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20111201

• Synthesis, stereochemistry and SAR of a series of minodronate analogues as RGGT inhibitors.

  European journal of medicinal chemistry 20111001

• A serendipitous phosphonocarboxylate complex of boron: when vessel becomes reagent.

  Chemical communications (Cambridge, England) 20110614

• [Minodronic acid- its clinical efficacy and prospects for once-a-month dosing regimen].

  Clinical calcium 20110101

• Nitrogen-containing bisphosphonate, YM529/ONO-5920, inhibits tumor metastasis in mouse melanoma through suppression of the Rho/ROCK pathway.

  Clinical & experimental metastasis 20101001

• Minodronate for the treatment of osteoporosis.

  Drugs of today (Barcelona, Spain : 1998) 20100101

• [Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20090901

• Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20090801

• A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis.

  Bone 20090601

• [Drugs under development for osteoporosis ].

  Nihon rinsho. Japanese journal of clinical medicine 20090501

• [New development in bisphosphonate treatment. Review of effect on bone metabolism by minodronic acid in primary osteoporosis].

  Clinical calcium 20090101

• [New development in bisphosphonate treatment. Review of the preventive effect of minodronic acid on fracture in Japanese patients with osteoporosis].

  Clinical calcium 20090101

• New bisphosphonates and trends in drug therapy for osteoporosis: preface.

  Clinical calcium 20090101

• Long-term minodronic acid (ONO-5920/YM529) treatment suppresses increased bone turnover, plus prevents reduction in bone mass and bone strength in ovariectomized rats with established osteopenia.

  Bone 20081101

• Minodronic acid (ONO-5920/YM529) prevents decrease in bone mineral density and bone strength, and improves bone microarchitecture in ovariectomized cynomolgus monkeys.

  Bone 20081101

• Minodronic acid, a third-generation bisphosphonate, antagonizes purinergic P2X(2/3) receptor function and exerts an analgesic effect in pain models.

  European journal of pharmacology 20080728

• Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells.

  Cancer chemotherapy and pharmacology 20080601

• Farnesyl pyrophosphate synthase enantiospecificity with a chiral risedronate analog, [6,7-dihydro-5H-cyclopenta[c]pyridin-7-yl(hydroxy)methylene]bis(phosphonic acid) (NE-10501): Synthetic, structural, and modeling studies.

  Bioorganic & medicinal chemistry letters 20080501

• Nitrogen-containing bisphosphonate, YM529/ONO-5920, inhibits macrophage inflammatory protein 1 alpha expression and secretion in mouse myeloma cells.

  Cancer science 20080101

• [New bone density conservation agents for osteoporosis under research and development: Minodronic acid].

  Nihon rinsho. Japanese journal of clinical medicine 20071128

• Induction of mitochondria-dependent apoptosis through the inhibition of mevalonate pathway in human breast cancer cells by YM529, a new third generation bisphosphonate.

  Cancer letters 20070808

• [Therapeutic agents for disorders of bone and calcium metabolism: Minodronic acid hydrate].

  Clinical calcium 20070101

• Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines.

  BMC cancer 20070101

• Minodronic acid influences receptor activator of nuclear factor kappaB ligand expression and suppresses bone resorption by osteoclasts in rats with collagen-induced arthritis.

  Modern rheumatology 20070101

• A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo.

  British journal of cancer 20061120

• Minodronate suppresses prostaglandin F2alpha-induced vascular endothelial growth factor synthesis in osteoblasts.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20060301

• Minodronate, a nitrogen-containing bisphosphonate, is a promising remedy for treating patients with diabetic retinopathy.

  Medical hypotheses 20060101

• Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050915

• Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2.

  Biochemical and biophysical research communications 20050304

• A third-generation bisphosphonate, minodronic acid (YM529), augments the interferon alpha/beta-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050115

• [Minodronic acid hydrate as a new therapeutic agent for osteoporosis].

  Clinical calcium 20050101

• Minodronate, a nitrogen-containing bisphosphonate, inhibits advanced glycation end product-induced vascular cell adhesion molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation.

  International journal of tissue reactions 20050101

• Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling.

  The American journal of pathology 20041201

• Effects of YM529, a novel minodronic acid, on adjuvant arthritis in rats.

  Clinical and experimental rheumatology 20040101

• Combined therapy with a new bisphosphonate, minodronate (YM529), and chemotherapy for multiple organ metastases of small cell lung cancer cells in severe combined immunodeficient mice.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20031101

• A new bisphosphonate, YM529 induces apoptosis in HL60 cells by decreasing phosphorylation of single survival signal ERK.

  Life sciences 20031010

• Nitrogen-containing bisphosphonates induce S-phase cell cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway.

  Cellular signalling 20030701

• Effect of minodronic acid (ONO-5920) on bone mineral density and arthritis in adult rats with collagen-induced arthritis.

  Arthritis and rheumatism 20030601

• A new stressed test to predict the foreign matter formation of minodronic acid in solution.

  International journal of pharmaceutics 20030130

• Failure of stability prediction for minodronic acid injectable by accelerated stability testing.

  International journal of pharmaceutics 20020708

• Synergistic growth inhibition of YM529 with biologic response modifiers (BRMs) in myeloma cells.

  International journal of hematology 20020601

• Conflicting actions of parathyroid hormone-related protein and serum calcium as regulators of 25-hydroxyvitamin D(3)-1 alpha-hydroxylase expression in a nude rat model of humoral hypercalcemia of malignancy.

  The Journal of endocrinology 20011101

• Stabilization of minodronic acid in aqueous solution for parenteral formulation.

  International journal of pharmaceutics 20010703

• A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells.

  Leukemia research 20010101